Clinical characteristics, management, and prevention of coronavirus disease 2019

Abstract

Coronavirus disease 2019 (COVID-19) is the third severe acute respiratory disease of the 21st century and the most aggressive global pandemic to date. The whole population has been susceptible to the disease, particularly the emerging variants of the virus. The core pathophysiological mechanism is viral sepsis that can lead to the respiratory tract disorders and even systemic disorders such as cytokine release syndrome, thrombosis, abnormal angiogenesis, and multiple organ dysfunction. Despite only few licensed treatments to date, rapid advances have been made in exploring the effectiveness and safety of pharmacological interventions and vaccines. However, three pillars of preventative and control measures - proactive contact tracing, wearing facial masks, and social distancing - are essential to combat the ongoing pandemic. As the number of patients recovering from COVID-19 rapidly increases, the world has entered the era of caring for patients during the convalescence phase. This phase still represents a largely unmet medical need globally.

Keywords

COVID-19 / antibody / variant / anti-viral drug / vaccine

References

[[1]] Koh D, Sng J. Lessons from the past: perspectives on severe acute respiratory syndrome. Asia Pac J Public Health, 2010; 22(3): 132S-136S.

[[2]] Donnelly C A, Malik M R, Elkholy A, et al. Worldwide Reduction in MERS Cases and Deaths since 2016. Emerg Infect Dis, 2019; 25(9): 1758-1760.

[[3]] World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/.WHOAccessed on 07 December, 2022

[[4]] Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020; 382(8): 727-733.

[[5]] Zhang Y Z, Holmes E C. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell, 2020; 181(2): 223-227.

[[6]] Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol, 2020; 7(10): e737-e745.

[[7]] Chan J F, Yuan S, Kok K H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020; 395(10223): 514-23.

[[8]] Guan W J, Ni Z Y, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med, 2020; 382(18): 1708-1720.

[[9]] Chan J F, Poon V K, Chan C C, et al. Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters. Clin Infect Dis, 2021; 75: e1101-e1111.

[[10]] Liu M, Li Z, Liu M, et al. Association between temperature and COVID-19 transmission in 153 countries. Environ Sci Poll Res Int, 2022; 29(11): 16017-16027.

[[11]] Tian F, Liu X, Chao Q, et al. Ambient air pollution and low temperature associated with case fatality of COVID-19: A nationwide retrospective cohort study in China. Innovation, 2021; 2(3): 100139.

[[12]] Carta M G, Minerba L, Demontis R, et al. The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature. J Pub Health Res, 2021; 10(4): 2303.

[[13]] Zhu G, Zhu Y, Wang Z, et al. The association between ambient temperature and mortality of the coronavirus disease 2019 (COVID-19) in Wuhan, China: a time-series analysis. BMC Public Health, 2021; 21(1): 117.

[[14]] Chinazzi M, Davis J T, Ajelli M, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science, 2020; 368(6489): 395-400.

[[15]] Clapp P W, Sickbert-Bennett E E, Samet J M, et al. Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic. JAMA Intern Med, 2021; 181(4): 463-469.

[[16]] Koo J R, Cook A R, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. Lancet Infect Dis, 2020; 20(6): 678-688.

[[17]] Shi Q, Hu Y, Peng B, et al. Effective control of SARS-CoV-2 transmission in Wanzhou, China. Nat Med, 2021; 27(1): 86-93.

[[18]] Chen S, Zhang Z, Yang J, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. Lancet, 2020; 395(10232): 1305-1314.

[[19]] Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science, 2020; 368(6490): 489-493.

[[20]] Poustchi H, Darvishian M, Mohammadi Z, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis, 2021; 21(4): 473-481.

[[21]] Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti- SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet, 2020; 396(10247): 313-319.

[[22]] Pallett S J C, Rayment M, Patel A, et al. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study. Lancet Respir Med, 2020; 8(9): 885-894.

[[23]] Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med, 2020; 26(8): 1193-1195.

[[24]] Li C, Luo F, Liu C, et al. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. Ann Med, 2021; 53(1): 391-401.

[[25]] Bajema K L, Wiegand R E, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med, 2021; 181(4): 450-460.

[[26]] Hallal P C, Hartwig F P, Horta B L, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. Lancet Glob Health, 2020; 8(11): e1390-e1398.

[[27]] Zhou P, Yang X L, Wang X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020; 579(7798): 270-273.

[[28]] Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020; 579(7798): 265-269.

[[29]] McCallum M, De Marco A, Lempp FA, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, 2021; 184(9): 2332-2347.

[[30]] Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell host Microbe, 2021; 29: 819-833.

[[31]] Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, 2020; 369(6504): 650-655.

[[32]] Liu L, Wang P, Nair M S, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature, 2020; 584(7821): 450-456.

[[33]] Johnson B A, Xie X, Bailey A L, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature, 2021; 591(7849): 293-299.

[[34]] Zhou Z, Huang C, Zhou Z, et al. Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor for human CD14(+) monocytes. iScience, 2021; 24(3): 102187.

[[35]] Golden J W, Cline C R, Zeng X, et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight, 2020; 5(19): e142032.

[[36]] Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE 2 transgenic mice. Nature, 2020; 583(7818): 830-833.

[[37]] Jiang R D, Liu M Q, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing Human Angiotensin-Converting Enzyme 2. Cell, 2020; 182(1): 50-58.

[[38]] Zheng J, Wong LR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature, 2021; 589(7843): 603-607.

[[39]] Dinnon K H 3rd, Leist S R, Schäfer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature, 2020; 586(7830): 560-566.

[[40]] Rathnasinghe R, Strohmeier S, Amanat F, et al. Comparison of transgenic and adenovirus hACE 2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect, 2020; 9(1): 2433-2445.

[[41]] Sun J, Zhuang Z, Zheng J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell, 2020; 182(3): 734-743.

[[42]] Munster V J, Feldmann F, Williamson B N, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature, 2020; 585(7824): 268-272.

[[43]] Deng W, Bao L, Gao H, et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. Nat Comm, 2020; 11(1): 4400.

[[44]] Chandrashekar A, Liu J, Martinot A J, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020; 369(6505): 812-817.

[[45]] Feng L, Wang Q, Shan C, et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Comm, 2020; 11(1): 4207.

[[46]] Yu J, Tostanoski L H, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020; 369(6505): 806-11.

[[47]] Yuan S, Yin X, Meng X, et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature, 2021; 593: 418-423.

[[48]] Fox S E, Akmatbekov A, Harbert J, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med, 2020; 8(7): 681-686.

[[49]] Schurink B, Roos E, Radonic T, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe, 2020; 1(7): e290-e299.

[[50]] Ackermann M, Verleden S E, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med, 2020; 383(2): 120-128.

[[51]] McGonagle D, O'Donnell J S, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol, 2020; 2(7): e437-e445.

[[52]] Hanley B, Naresh K N, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe, 2020; 1(6): e245-e253.

[[53]] Puelles V G, Lütgehetmann M, Lindenmeyer M T, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med, 2020; 383(6): 590-592.

[[54]] Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 2020; 395(10235): 1517-1520.

[[55]] Feng E, Balint E, Poznanski S M, et al. Aging and interferons: impacts on inflammation and viral disease outcomes. Cells, 2021; 10(3): 708.

[[56]] Ballow M, Haga C L. Why do some people develop serious COVID-19 Disease after infection, while others only exhibit mild symptoms? J Allergy Clin Immunol Pract, 2021; 9(4): 1442-1448.

[[57]] Fajgenbaum D C, June C H. Cytokine storm. N Engl J Med, 2020; 383(23): 2255-2273.

[[58]] Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect dis, 2020; 20(11): e276-288.

[[59]] Wölfel R, Corman V M, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020; 581(7809): 465-469.

[[60]] He X, Lau E H Y, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med, 2020; 26(5): 672-675.

[[61]] To K K, Tsang O T, Leung W S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis, 2020; 20(5): 565-574.

[[62]] Guo W L, Jiang Q, Ye F, et al. Effect of throat washings on detection of 2019 Novel Coronavirus. Clin Infect Dis, 2020; 71(8): 1980-1981.

[[63]] Shan D, Johnson J M, Fernandes S C, et al. N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nat Comm, 2021; 12(1): 1931.

[[64]] Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe, 2021; 2(1): e13-22.

[[65]] Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest, 2020; 130(10): 5235-5244.

[[66]] Hong K, Cao W, Liu Z, et al. Prolonged presence of viral nucleic acid in clinically recovered COVID-19 patients was not associated with effective infectiousness. Emerg Microbe Infect, 2020; 9(1): 2315-2321.

[[67]] Boum Y, Fai K N, Nicolay B, et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet Infect Dis, 2021; 21: 1089-1096.

[[68]] Long Q X, Liu B Z, Deng H J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Natmed, 2020; 26(6): 845-848.

[[69]] Yu H Q, Sun B Q, Fang Z F, et al. Distinct features of SARS-CoV- 2-specific IgA response in COVID-19 patients. Eur Respir J, 2020; 56(2): 2001526.

[[70]] Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med, 2021; 13(577): eabd2223.

[[71]] Chen M, Qin R, Jiang M, et al. Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review. Int J Infect Dis, 2021; 104: 415-422.

[[72]] Niu X, Li S, Li P, et al. Longitudinal analysis of T and B cell receptor repertoire transcripts reveal dynamic immune response in COVID-19 patients. Front Immunol, 2020; 11: 582010.

[[73]] Wilk A J, Rustagi A, Zhao N Q, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med, 2020; 26(7): 1070.

[[74]] Bost P, Giladi A, Liu Y, et al. Host-Viral infection maps reveal signatures of severe COVID-19 Patients. Cell, 2020; 181(7): 1475-1488.

[[75]] Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med, 2020; 26(6): 842-844.

[[76]] Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021; 184: 2939-2954.

[[77]] Emary K R W, Golubchik T, Aley P K, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, 2021; 397(10282): 1351-1362.

[[78]] Challen R, Brooks-Pollock E, Read J M, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ, 2021; 372: n579.

[[79]] Frampton D, Rampling T, Cross A, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis, 2021; 21: 1246-1256.

[[80]] Keehner J, Horton L E, Pfeffer M A, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med, 2021; 384(18): 1774-1775.

[[81]] Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell, 2021; 184(9): 2362-2371.

[[82]] Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021; 184(9): 2348-2461.

[[83]] Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell, 2021; 184(9): 2384-2393.

[[84]] Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet, 2022; 399(10323): 437-446.

[[85]] Abu-Raddad L J, Chemaitelly H, Butt A A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. BMJ Med, 2022; 12(3): 386.

[[86]] Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med, 2021; 384: 1899-1909.

[[87]] Shen X, Tang H, Pajon R, et al. Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. N Engl J Med, 2021; 384: 2352-2354.

[[88]] Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021; 184(8): 2201-2211.

[[89]] Madhi S A, Baillie V, Cutland C L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med, 2021; 384: 1885-1898.

[[90]] Moyo-Gwete T, Madzivhandila M, Makhado Z, et al. Cross- Reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med, 2021; 384: 2161-2163.

[[91]] Wang G L, Wang Z Y, Duan L J, et al. Susceptibility of circulating SARS-CoV-2 variants to Neutralization. N Engl J Med, 2021; 384: 2354-2356.

[[92]] Lustig Y, Nemet I, Kliker L, et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2. N Engl J Med, 2021; 384: 2453-2454.

[[93]] Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med, 2022; 386: 1532-1546.

[[94]] Pajon R, Doria-Rose N A, Shen X, et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med, 2022; 386(11): 1088-1091.

[[95]] Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA Vaccine against Omicron. N Engl J Med, 2022; 386: 1377-1380.

[[96]] Chia W N, Zhu F, Ong S W X, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, 2021; 2: e240-249.

[[97]] Hansen C H, Michlmayr D, Gubbels S M, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet, 2021; 397(10280): 1204-1212.

[[98]] Hall V J, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet, 2021; 397(10283): 1459-1469.

[[99]] Letizia A G, Ge Y, Vangeti S, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med, 2021; 9: 712-720.

[[100]] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020; 395(10223): 507-513.

[[101]] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020; 323(11): 1061-1069.

[[102]] Feldstein L R, Rose E B, Horwitz S M, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med, 2020; 383(4): 334-346.

[[103]] Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 2020; 20(4): 425-434.

[[104]] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020; 395(10229): 1054-1062.

[[105]] Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PloS One, 2020; 15(11): e0241536.

[[106]] Long Q X, Tang X J, Shi Q L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med, 2020; 26(8): 1200-1204.

[[107]] Yang M, Li L, Huang T, et al. SARS-CoV-2 detected on environmental fomites for both asymptomatic and symptomatic patients with COVID-19. Am J Respir Crit Care Med, 2021; 203(3): 374-378.

[[108]] Melis M, Littera R. Undetected infectives in the Covid-19 pandemic. Int J Infect Dis, 2021; 104: 262-268.

[[109]] Davies N G, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med, 2020; 26(8): 1205-1211.

[[110]] Ahrenfeldt L J, Otavova M, Christensen K, et al. Sex and age differences in COVID-19 mortality in Europe&nbsp. Res Sq, 2020; rs.3.rs-61444.

[[111]] Torres Acosta M A, Singer B D. Pathogenesis of COVID-19- induced ARDS: implications for an ageing population. Eur Respir J, 2020; 56(3): 2002049.

[[112]] Koff W C, Williams M A. Covid-19 and immunity in aging populations - a new research agenda. N Engl J Med, 2020; 383(9): 804-805.

[[113]] Wang X Q, Song G, Yang Z, et al. Association between ageing population, median age, life expectancy and mortality in coronavirus disease (COVID-19). Aging, 2020; 12(24): 24570-24578.

[[114]] Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med, 2020; 288(4): 469-476.

[[115]] Guan W J, Laing W H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J, 2020; 55(5): 2000547.

[[116]] Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 fection: a nationwide analysis in China. Lancet Oncol, 2020; 21(3): 335-337.

[[117]] Guan W J, Liang W H, Shi Y, et al. Chronic respiratory diseases and the outcomes of COVID-19: a nationwide retrospective cohort study of 39,420 Cases. J Allergy Clin Immunol Pract, 2021; 9: 2645-2655.

[[118]] Bloom C I, Drake T M, Docherty A B, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med, 2021; 9: 699-711.

[[119]] Calmes D, Graff S, Maes N, et al. Asthma and COPD are not risk factors for ICU stay and death in case of SARS-CoV2 Infection. J Allergy Clin Immunol Pract, 2021; 9(1): 160-169.

[[120]] Skevaki C, Karsonova A, Karaulov A, et al. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol, 2020; 146(6): 1295-1301.

[[121]] Song J, Zeng M, Wang H, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy, 2021; 76(2): 483-496.

[[122]] World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. https://apps.who.int/iris/ handle/10665/332196Accessed on December 2022.

[[123]] Wei P F. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl), 2020; 133(9): 1087-1095.

[[124]] International Severe Acute Respiratory and emerging Infection Consortium. https://isaric.tghn.org/Accessed on December 2022.

[[125]] Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020; 583(7816): 437-40.

[[126]] Chen R, Sang L, Jiang M, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol, 2020; 146(1): 89-100.

[[127]] Shen B, Yi X, Sun Y. et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell, 2020; 182(1): 59-72.

[[128]] Ren L, Wang Y, Zhong J, et al. Dynamics of the upper respiratory tract microbiota and its association with mortality in COVID-19. Am J Respir Crit Care Med, 2021; 204(12): 1379-1390.

[[129]] Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med, 2020; 180(8): 1081-9.

[[130]] Alemany A, Bar C B, Ouchi D, et al. Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. J Infect, 2021; 82(5): 186-230.

[[131]] Kitagawa Y, Orihara Y, Kawamura R, et al. Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using loop-mediated isothermal amplification. J Clin Virol, 2020; 129: 104446.

[[132]] Xing W, Liu Y, Wang H, et al. A high-throughput, multi-index isothermal amplification platform for rapid detection of 19 types of common respiratory viruses including SARS-CoV-2. Engineering, 2020; 6(10): 1130-1140.

[[133]] Xing W, Wang J, Zhao C, et al. A highly automated mobile laboratory for on-site molecular diagnostics in the COVID-19 pandemic. Clin Chem, 2021; 67(4): 672-683.

[[134]] Joung J, Ladha A, Saito M, et al. Detection of SARS-CoV-2 with sherlock one-pot testing. N Engl J Med, 2020; 383(15): 1492-1494.

[[135]] Brendish N J, Poole S, Naidu V V, et al. Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. Lancet Respir Med, 2020; 8(12): 1192-1200.

[[136]] Gibani M M, Toumazou C, Sohbati M, et al. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. Lancet Microbe, 2020; 1(7): e300-307.

[[137]] Zhang K, Liu X, Shen J, et al. Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID-19 pneumonia using computed tomography. Cell, 2020; 182(5): 1360.

[[138]] Mei X, Lee H C, Diao K Y, et al. Artificial intelligence-enabled rapid diagnosis of patients with COVID-19. Nat Med, 2020; 26(8): 1224-1228.

[[139]] Jiao Z, Choi J W, Halsey K, et al. Prognostication of patients with COVID-19 using artificial intelligence based on chest x-rays and clinical data: a retrospective study. Lancet Digit Health, 2021; 3(5): e286-294.

[[140]] Wang G, Liu X, Shen J, et al. A deep-learning pipeline for the diagnosis and discrimination of viral, non-viral and COVID-19 pneumonia from chest X-ray images. Nat Biomed Eng, 2021; 5: 943.

[[141]] Menni C, Valdes A M, Freidin M B, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med, 2020; 26(7): 1037-1040.

[[142]] Mendels D A, Dortet L, Emeraud C, et al. Using artificial intelligence to improve COVID-19 rapid diagnostic test result interpretation. Proc Natl Aca Sci, 2021; 118(12): :e2019893118.

[[143]] Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 2020; 382(19): 1787-1799.

[[144]] Recovery Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (Recovery): a randomised, controlled, open-label, platform trial. Lancet, 2020; 396(10259): 1345-1352.

[[145]] Panerai S, Raggi A, Tasca D, et al. Telephone-based reality orientation therapy for patients with dementia: a pilot study during the COVID-19 outbreak. Am J Occup Ther, 2021; 75(2): 1-9.

[[146]] Hung I F, Lung K C, Tso E Y, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020; 395(10238): 1695-1704.

[[147]] Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med, 2022; 386: 1397-1408.

[[148]] Goldman J D, Lye D C B, Hui D S, et al. Remdesivir for 5 or 10 Days in patients with severe Covid-19. N Engl J Med, 2020; 383(19): 1827-1837.

[[149]] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020; 395(10236): 1569-1578.

[[150]] Beigel J H, Tomashek K M, Dodd L E, et al. Remdesivir for the treatment of Covid-19-final report. N Engl J Med, 2020; 383(19): 1813-1826.

[[151]] Spinner C D, Gottlieb R L, Criner G J, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA, 2020; 324(11): 1048-1057.

[[152]] Yan D, Liu X Y, Zhu Y N, et al. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J, 2020; 56(1): 2000799.

[[153]] Gottlieb R L, Vaca C E, Paredes R, et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med, 2022; 386(4): 305-315.

[[154]] Jayk Bernal A, Gomes da Silva M M, Musungaie D B, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med, 2022; 386(6): 509-520.

[[155]] Reis G, Silva E, Silva D C M, et al. Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med, 2022; 386: 1721-1731.

[[156]] Cavalcanti A B, Zampieri FG, Rosa R G, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med, 2020; 383(21): e119.

[[157]] Self W H, Semler M W, Leither L M, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA, 2020; 324(21): 2165-2176.

[[158]] Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 2020; 369: m1849.

[[159]] Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med, 2020; 383(21): 2030-2040.

[[160]] Boulware D R, Pullen M F, Bangdiwala A S, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med, 2020; 383(6): 517-525.

[[161]] Mitjà O, Corbacho-Monné M, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med, 2021; 384(5): 417-427.

[[162]] Zhao H, Zhang C, Zhu Q, et al. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial. Int Immunopharmacol, 2021; 97: 107702.

[[163]] Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol, 2021; 95: 107522.

[[164]] López-Medina E, López P, Hurtado I C, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA, 2021; 325(14): 1426-1435.

[[165]] Monk P D, Marsden R J, Tear V J, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med, 2021; 9(2): 196-206.

[[166]] Tomazini B M, Maia I S, Cavalcanti A B, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA, 2020; 324(13): 1307-1316.

[[167]] Horby P, Lim W S, Emberson J R, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med, 2021; 384(8): 693-704.

[[168]] Angus D C, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA, 2020; 324(13): 1317-1329.

[[169]] Dequin P F, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among Critically Ill patients with COVID-19: a randomized clinical trial. JAMA, 2020; 324(13): 1298-1306.

[[170]] Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, 2020; 180(7): 934-943.

[[171]] Kalil A C, Patterson T F, Mehta A K, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med, 2021; 384(9): 795-807.

[[172]] Lenze E J, Mattar C, Zorumski C F, et al. Fluvoxamine vs Placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA, 2020; 324(22): 2292-2300.

[[173]] Ramakrishnan S, Nicolau D V, Jr Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med, 2021; 9(7): 763-772.

[[174]] Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (Principle): a randomised, controlled, open-label, adaptive platform trial. Lancet, 2021; 397(10279): 1063-1074.

[[175]] Bhattacharya B, Kumar R, Meena V P, et al. SARS-CoV-2 RT-PCR profile in 298 Indian COVID-19 patients: a retrospective observational study. Path Dis, 2021; 79(1): 64.

[[176]] Furtado R H M, Berwanger O, Fonseca H A, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION Ⅱ ): a randomised clinical trial. Lancet, 2020; 396(10256): 959-967.

[[177]] Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol, 2020; 146(1): 137-146.

[[178]] Murai I H, Fernandes A L, Sales L P, et al. Effect of a single high dose of Vitamin D 3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA, 2021; 325(11): 1053-1060.

[[179]] Recovery Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (Recovery): a randomised, controlled, open-label, platform trial. Lancet Respir Med, 2021; 9(12): 1419-1426.

[[180]] Gordon A C, Mouncey P R, Al-Beidh F, et al. Interleukin-6 receptor antagonists in Critically Ill patients with Covid-19. N Engl J Med, 2021; 384(16): 1491-1502.

[[181]] Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (Recovery): a randomised, controlled, open-label, platform trial. Lancet, 2021; 397(10285): 1637-1645.

[[182]] Rosas I O, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med, 2021; 384(16): 1503-1516.

[[183]] Hermine O, Mariette X, Tharaux P L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med, 2021; 181(1): 32-40.

[[184]] Veiga V C, Prats J, Farias D L C, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, 2021; 372: n84.

[[185]] Soin A S, Kumar K, Choudhary N S, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med, 2021; 9(5): 511-521.

[[186]] Stone J H, Frigault M J, Serling-Boyd N J, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med, 2020; 383(24): 2333-2344.

[[187]] Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med, 2021; 181(1): 24-31.

[[188]] Lescure F X, Honda H, Fowler R A, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021; 9(5): 522-532.

[[189]] Cremer P C, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol, 2021; 3: e410-e418.

[[190]] Cheng L L, Guan W J, Duan C Y, et al. Effect of recombinant human granulocyte colony-stimulating factor for patients with Coronavirus Disease 2019 (COVID-19) and lymphopenia: a randomized clinical trial. JAMA Intern Med, 2021; 181(1): 71-78.

[[191]] Okoh A K, Bishburg E, Grinberg S, et al. Tocilizumab use in COVID- 19-associated pneumonia. J Med Virol, 2021; 93(2): 1023-1028.

[[192]] Vlaar A P J, de Bruin S, Busch M, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol, 2020; 2(12): e764-773.

[[193]] Cheng Y, Wong R, Soo Y O, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis, 2005; 24(1): 44-46.

[[194]] Weinreich D M, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med, 2021; 384(3): 238-251.

[[195]] Wang J, Zheng X, Chen J. Clinical progression and outcomes of 260 patients with severe COVID-19: an observational study. Sci Rep, 2021; 11(1): 3166.

[[196]] Gottlieb R L, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA, 2021; 325(7): 632-644.

[[197]] Andreano E, Nicastri E, Paciello I, et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 2021; 184(7): 1821-1835.

[[198]] Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med, 2021; 384(7): 610-618.

[[199]] Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase Ⅱ multicentre randomised controlled trial (PLACID Trial). BMJ, 2020; 371: m3939.

[[200]] Simonovich V A, Burgos Pratx L D, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med, 2021; 384(7): 619-629.

[[201]] Lundgren J D, Grund B, Barkauskas C E, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med, 2021; 384(10): 905-914.

[[202]] Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020; 324(5): 460-470.

[[203]] Janiaud P, Axfors C, Schmitt A M, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA, 2021; 325(12): 1185-1195.

[[204]] Sullivan D J, Gebo K A, Shoham S, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med, 2022; 386: 1700-1711.

[[205]] Mancia G, Rea F, Ludergnani M, et al. Renin-Angiotensin- Aldosterone system blockers and the risk of Covid-19. N Engl J Med, 2020; 382(25): 2431-2440.

[[206]] Reynolds H R, Adhikari S, Pulgarin C, et al. Renin-Angiotensin- Aldosterone system inhibitors and risk of Covid-19. N Engl J Med, 2020; 382(25): 2441-2448.

[[207]] Morales D R, Conover M M, You S C, et al. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit health, 2021; 3(2): e98-114.

[[208]] =Mehta N, Kalra A, Nowacki A S, et al. Association of use of angiotensin-converting enzyme inhibitors and Angiotensin Ⅱ receptor blockers with testing positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 2020; 5(9): 1020-1026.

[[209]] de Abajo F J, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet, 2020; 395(10238): 1705-1714.

[[210]] Lopes R D, Macedo A V S, de Barros E Silva P G M, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and Angiotensin Ⅱ receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA, 2021; 325(3): 254-264.

[[211]] Cohen J B, Hanff T C, William P, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med, 2021; 9(3): 275-284.

[[212]] Haas E J, Angulo F J, McLaughlin J M, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet, 2021; 397: 1819-1829.

[[213]] Anderson E J, Rouphael N G, Widge A T, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med, 2020; 383(25): 2427-2438.

[[214]] Walsh E E, Frenck R W Jr, Falsey A R, et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med, 2020; 383(25): 2439-2450.

[[215]] Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med, 2020; 383(24): 2320-2332.

[[216]] Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med, 2021; 384: 2187-2201.

[[217]] Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med, 2021; 384: 1824-1835.

[[218]] Polack F P, Thomas S J, Kitchin N, et al. Safety and efficacy of the BNT162b 2 mRNA Covid-19 vaccine. N Engl J Med, 2020; 383(27): 2603-2615.

[[219]] Baden L R, El Sahly H M, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med, 2021; 384(5): 403-416.

[[220]] Dagan N, Barda N, Kepten E, et al. BNT162b 2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med, 2021; 384(15): 1412-1423.

[[221]] Goepfert P A, Fu B, Chabanon A L, et al. Safety and immunogenicity of SARS-CoV-2 recombnant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Lancet Infect Dis, 2021; 21: 1257-1270.

[[222]] Stephenson K E, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA, 2021; 325(15): 1535-44.

[[223]] Monin L, Laing A G, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol, 2021; 22: 765-778.

[[224]] Folegatti P M, Ewer K J, Aley P K, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020; 396(10249): 467-78.

[[225]] Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 2021; 21(1): 39-51.

[[226]] Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021; 21(2): 181-192.

[[227]] Zhu F C, Guan X H, Li Y H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020; 396(10249): 479-488.

[[228]] Logunov D Y, Dolzhikova I V, Shcheblyakov D V, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021; 397(10275): 671-681.

[[229]] Ramasamy M N, Minassian A M, Ewer K J, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, 2021; 396(10267): 1979-1993.

[[230]] Voysey M, Clemens S A C, Madhi S A, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 2021; 397(10269): 99-111.

[[231]] Voysey M, Costa Clemens S A, Madhi S A, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx 1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, 2021; 397(10277): 881-891.

[[232]] Ella R, Vadrevu K M, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis, 2021; 21(5): 637-646.

[[233]] Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet, 2021; 397(10275): 682-694.

[[234]] Chappell K J, Mordant F L, Li Z, et al. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis, 2021; 21: 1383-1394.

[[235]] Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA, 2020; 324(10): 951-960.

[[236]] Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021; 21: 803-812.

[[237]] Greinacher A, Thiele T, Warkentin T E, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med, 2021.

[[238]] Schultz N H, Sørvoll I H, Michelsen A E, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med, 2021.

[[239]] Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med, 2021; 384: 2202-2211.

[[240]] Muir K L, Kallam A, Koepsell S A, et al. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med, 2021; 384: 1964-1965.

[[241]] Pottegård A, Lund L C, Karlstad Ø, et al. Events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ, 2021; 373: n1114.

[[242]] Goldberg Y, Mandel M, Bar-On Y M, et al. Waning immunity after the BNT162b 2 vaccine in israel. n engl j med, 2021; 385(24): e85.

[[243]] Levin E G, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med, 2021; 385(24): e84.

[[244]] Atmar R L, Lyke K E, Deming M E, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med, 2022; 386(11): 1046-1057.

[[245]] Stuart A S V, Shaw R H, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, 2022; 399(10319): 36-49.

[[246]] Munro A P S, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 2021; 398(10318): 2258-2276.

[[247]] Rearte A, Castelli J M, Rearte R, et al. Effectiveness of rAd26- rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. Lancet, 2022; 399(10331): 1254-1264.

[[248]] Costa Clemens S A, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet, 2022; 399(10324): 521-529.

[[249]] Widge A T, Rouphael N G, Jackson L A, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med, 2021; 384(1): 80-82.

[[250]] Doria-Rose N, Suthar M S, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med, 2021; 384: 2259-2261.

[[251]] Wang Z, Wang Y, Yang Z, et al. The use of non-invasive ventilation in COVID-19: a systematic review. Int J Infect Dis, 2021; 106: 254-261.

[[252]] Schünemann H J, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of Coronavirus disease, including COVID-19: a living systematic review of multiple streams of evidence. Ann Intern Med, 2020; 173(3): 204-216.

[[253]] Grieco D L, Menga L S, Cesarano M, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA, 2021; 325(17): 1731-1743.

[[254]] Sartini C, Tresoldi M, Scarpellini P, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. JAMA, 2020; 323(22): 2338-2340.

[[255]] Coppo A, Bellani G, Winterton D, et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respir Med, 2020; 8(8): 765-774.

[[256]] Botta M, Tsonas A M, Pillay J, et al. Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. Lancet Respir Med, 2021; 9(2): 139-148.

[[257]] Barbaro R P, MacLaren G, Boonstra P S, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet, 2020; 396(10257): 1071-1078.

[[258]] Schmidt M, Hajage D, Lebreton G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med, 2020; 8(11): 1121-1131.

[[259]] Lebreton G, Schmidt M, Ponnaiah M, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respir Med, 2021; 9: 851-862.

[[260]] Bharat A, Machuca T N, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med, 2021; 9(5): 487-497.

[[261]] Morin L, Savale L, Pham T, et al. Four-Month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA, 2021; 325(15): 1525-1534.

[[262]] Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med, 2021; 9(7): 747-754.

[[263]] Myall K J, Mukherjee B, Castanheira A M, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc, 2021; 18(5): 799-806.

[[264]] Taquet M, Geddes J R, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psych, 2021; 8(5): 416-427.

[[265]] Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with Covid-19: retrospective cohort study. BMJ, 2021; 372: n693.

[[266]] Aldhahir A M, Aldabayan Y S, Alqahtani J S, et al. A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study. ERJ Open Res, 2021; 7(1): 747-754.

[[267]] Center for Global Development. Financing for Global Health Security and Pandemic Preparedness: Taking Stock and What’s Next. https://www.cgdev.org/blog/financing-global-health-security-and-pandemic-preparedness-taking-stock-whats-nextAccessed on December 2022.